The objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of healthcare companies. The Fund will aim to outperform the Benchmark over rolling three- and five-year periods as part of this objective. The Fund aims to achieve its investment objective by investing a minimum of 80% of its Net Asset Value in equity securities of healthcare companies. The Fund invests globally across developed markets, emerging markets, and Asia-Pacific (as further detailed below) in healthcare companies including pharmaceuticals, biotechnology, medical technology, and healthcare services as well as related industries including diagnostics companies, life sciences tools companies, digital health companies, specialty pharma companies and clinical research and manufacturing organisations. The Fund typically holds between 30 and 50 individual equity positions.